AMAM — Ambrx Biopharma Cashflow Statement
0.000.00%
Last trade - 00:00- $1.76bn
- $1.54bn
- $7.40m
Annual cashflow statement for Ambrx Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 20-F | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -22.3 | -17.8 | -68.3 | -78 |
| Depreciation | ||||
| Amortisation | ||||
| Non-Cash Items | 3.32 | 2.69 | 17.9 | 18.1 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | 14.2 | -7.38 | 3.64 | -10.6 |
| Change in Accounts Receivable | ||||
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -2.77 | -20.6 | -44.6 | -68.7 |
| Capital Expenditures | -0.048 | -0.252 | -3.21 | -1.05 |
| Purchase of Fixed Assets | ||||
| Purchase / Acquisition of Intangibles | ||||
| Other Investing Cash Flow Items | — | — | — | -45.7 |
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | -0.048 | -0.252 | -3.21 | -46.7 |
| Financing Cash Flow Items | — | — | -21 | 0.926 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | 0 | 95.7 | 127 | 0.928 |
| Foreign Exchange Effects | ||||
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | -2.85 | 75 | 79.6 | -114 |